Skip to content

About Us
Why P2B001
About PD
News & Events
- Press Releases
- Events
Contact Us

Menu

About Us
Why P2B001
About PD
News & Events
- Press Releases
- Events
Contact Us

News & Events

Press Releases

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group

December 5, 2024

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

November 11, 2024

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

September 4, 2024

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

July 22, 2024

Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders

November 9, 2023

Pharma Two B to Present Additional Phase 3 Positive Results of P2B001, a once-daily, fixed-dose combination of low-dose pramipexole and low-dose rasagiline, at 2023 International Congress of Parkinson’s Disease and Movement Disorders®

August 28, 2023

Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting

April 23, 2023

Pharma Two B Presents Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at the MDS International Congress of Parkinson’s Disease and Movement Disorders®

September 15, 2022

Pharma Two B Presents Late-Breaker Abstract on Positive Efficacy and Safety Data of P2B001 from Phase 3 Trial at American Academy of Neurology (AAN) Annual Meeting

April 5, 2022

Advances in Therapy publishes Pharma Two B’s review paper, “P2B001 (extended release pramipexole and rasagiline): A new treatment option in development for Parkinson’s disease”

March 14, 2022

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson’s Disease

December 15, 2021

Pharma Two B Announces Licensing and Investment Agreement with Myung In Pharm (MIP) for P2B001 in South Korea

November 18, 2021

Pharma Two B Announces Last Patient Out in Phase III Study of P2B001 in Early Parkinson’s Disease

September 13, 2021

Pharma Two B Appoints Jeffrey Berkowitz as Chairman of its Board of Directors

August 17, 2021

Pharma Two B Appoints Sheila Oren, M.D., M.B.A., as Chief Executive Officer

January 6, 2021

Pharma Two B Appoints David S. Tierney, M.D. as the Company’s Chief Executive Officer

February 18, 2020

First Patients Dosed in Phase III Multi-center, Multinational Study to Determine the Efficacy, Safety and Tolerability of P2B001 in Patients with Early Stage Parkinson’s Disease

February 6, 2018

A Randomized Trial of a Low Dose Rasagiline and Pramipexole Combination (P2B001) in Early Parkinson’s Disease

April 3, 2017

Pharma Two B Ltd. Closes $30 Million Financing Round

February 27, 2017

Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease

June 30, 2015

Pharma Two B Announces Positive Results in its Phase IIb Pivotal Clinical Study of P2B001 for the Treatment of Early Stage Parkinson’s Disease

June 30, 2015

Pharma Two B taking ‘synergistic’ approach in pursuit of 505(b)(2) approval

April 22, 2011

© 2022 Pharma Two B

Thank you!

An email was sent with access to our exclusive materials.
Please check your inbox and spam folder.

Please subscribe for this

Get this exclusive content straight to your email

Name

Email

.